Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of “Buy” from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK) has been given an average recommendation of “Buy” by the twelve ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $12.7778.

Several research firms recently weighed in on STTK. HC Wainwright lowered their target price on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Leerink Partners began coverage on shares of Shattuck Labs in a report on Monday, July 20th. They issued an “outperform” rating and a $16.00 target price for the company. Wall Street Zen cut shares of Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Needham & Company LLC increased their price target on shares of Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, June 8th.

Shattuck Labs Stock Performance

Shares of STTK stock opened at $7.04 on Monday. Shattuck Labs has a 12-month low of $0.97 and a 12-month high of $8.33. The stock has a market capitalization of $706.53 million, a P/E ratio of -13.80 and a beta of 1.08. The firm’s 50 day moving average is $7.05 and its 200 day moving average is $6.22.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). As a group, equities analysts predict that Shattuck Labs will post -0.44 earnings per share for the current year.

Insider Activity

In other Shattuck Labs news, insider Abhinav A. Shukla sold 23,365 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.08, for a total transaction of $165,424.20. Following the transaction, the insider owned 86,380 shares in the company, valued at $611,570.40. The trade was a 21.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Arundathy N. Pandite sold 30,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total transaction of $210,300.00. Following the completion of the sale, the insider directly owned 136,219 shares in the company, valued at approximately $954,895.19. This represents a 18.05% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 53,875 shares of company stock valued at $379,305. 8.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System bought a new stake in shares of Shattuck Labs during the 2nd quarter worth approximately $41,000. Legal & General Group Plc purchased a new stake in shares of Shattuck Labs during the second quarter valued at $41,000. Virtu Financial LLC purchased a new position in Shattuck Labs in the 3rd quarter worth about $38,000. Squarepoint Ops LLC bought a new stake in Shattuck Labs during the 3rd quarter valued at about $46,000. Finally, State of Wyoming bought a new position in Shattuck Labs in the 2nd quarter worth about $151,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.